Alnylam and Mayo Clinic Partner to Develop RNAi Parkinson s Drug

Oct 30, 2003

NEW YORK, Oct. 30 - Alnylam, of Cambridge, Mass., has formed a collaboration with researchers at the Mayo Clinic in Rochester, Minn., to develop an RNA interference-based drug that suppresses genes over-expressed in people with Parkinson's disease, the company said today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Warren Releases Genetic Ancestry Results

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Thirty-One Recommended for Removal

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz Dies

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

This Week in PLOS

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.

Main menu